arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

Arbutus Biopharma Corp

ABUS
$3.65 ▼ -0.42 (-10.32%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
39
Health
Weak
Bearish
auto_awesome

Analytical Summary

Arbutus Biopharma Corp faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $699.3M
Dividend Yield —
Revenue Growth 128.2% ↗
Op. Margin -271.0%
ROIC -39.4% ↗
FCF / Share $-0.21 ↗
Trailing P/E —
Price / Book 9.2x
FCF Yield —
Debt / Equity 0.00
info Valuation on last close. End-of-day price, Nov 5, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$14.08M
↑ +128.2% —
Net Income Profit after all expenses
$-33.50M
↑ +52.1% —
Operating Margin Operating profit as % of sales
-271.0%
↑ +37.1% 0th
FCF / Share Free cash flow per share
$-0.21
↑ +41.0% —
Long-Term Debt Long-term obligations
$0.00
— —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
1
Returns →
18
Financial Health
97
Cash Quality ↑
72

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 16 years · 57 quarters